Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Taysha Gene Therapies (Nasdaq: TSHA) has initiated screening for its Phase 1/2 REVEAL trial targeting Rett syndrome, with the first adult patient anticipated to be dosed in H1 2023. The company plans to submit a Clinical Trial Application to the UK MHRA and an IND to the U.S. FDA for TSHA-102 in pediatric patients in mid-2023 and H2 2023, respectively. Taysha's research and development expenses decreased significantly to $13.9 million in Q4 2022 from $37.9 million a year prior. Despite a net loss of $55.7 million for Q4 2022, the company holds $87.9 million in cash, expected to cover expenses into Q1 2024.
Taysha Gene Therapies (Nasdaq: TSHA) will disclose its financial results for Q4 and full-year 2022 on March 28, 2023, at 4:30 PM ET.
The conference call will provide updates on the company's progress in developing AAV-based gene therapies for rare CNS diseases. Participants can join via toll-free and international numbers. Taysha aims to eradicate monogenic CNS diseases by leveraging expertise and a robust gene therapy program.
Taysha Gene Therapies (Nasdaq: TSHA) provided an update on its TSHA-120 program for giant axonal neuropathy (GAN) following a Type B end-of-Phase 2 meeting with the FDA. The FDA acknowledged MFM32 as an acceptable endpoint and recommended dosing additional patients to support a Biologics License Application (BLA) submission. The company also announced the anticipated dosing of the first adult patient with Rett syndrome and plans to submit a Clinical Trial Application (CTA) in mid-2023. New management has implemented operational changes to enhance execution and milestones in 2023 are expected to drive key clinical developments.